The Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market is anticipated to grow by $2,397.67 million, at a CAGR of 21.2% from 2022 to 2027. Drug prices are high due to intricate production and R&D costs. To help manage these expenses, governments and healthcare organizations have created assistance programs and educational resources. These actions are expected to drive market growth and enhance adherence to treatments.